# A Study of the Efficacy and Safety of FXS6837 Capsules Compared to Eculizumab for 24 Weeks in Patients With PNH.

> **NCT07747090** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.** · enrollment: 90 (estimated)

## Conditions studied

- Paroxysmal Nocturnal Hemoglobinuria

## Interventions

- **DRUG:** FXS6837 Capsule
- **BIOLOGICAL:** Eculizumab infusion

## Key facts

- **NCT ID:** NCT07747090
- **Lead sponsor:** Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-12-10
- **Primary completion:** 2028-05-05
- **Final completion:** 2028-07-31
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07747090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07747090, "A Study of the Efficacy and Safety of FXS6837 Capsules Compared to Eculizumab for 24 Weeks in Patients With PNH.". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07747090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*